Frequently Asked Questions about Kisspeptin

A neuropeptide family encoded by the KISS1 gene; binds the KISS1R (GPR54) receptor on hypothalamic GnRH neurons and is the principal upstream switch of the reproductive hormone axis. The precursor is a 145-amino-acid protein cleaved to produce KP-54, KP-14, KP-13, and KP-10. All isoforms share a C-terminal RF-amide motif required for receptor binding.^[1]

Kisspeptin stimulates GnRH release from the hypothalamus, triggering the pituitary-gonadal hormone cascade. In published human studies, IV kisspeptin-10 raised LH pulse frequency and serum testosterone in healthy men within minutes of bolus administration. It acts upstream of the pituitary rather than as a direct hormone replacement.^[5][6]

In published research, yes — via an indirect upstream mechanism. IV kisspeptin-10 infusion (1.5 µg/kg/h) raised mean LH from 5.2 to 14.1 IU/L and elevated testosterone in healthy men (George 2011, JCEM).^[5] In men with type 2 diabetes and mild hypogonadism, a 0.3 µg/kg IV bolus normalized LH and testosterone over 11 hours (George 2013, Clinical Endocrinology).^[6] Kisspeptin acts at the hypothalamus; its testosterone effect depends on intact GnRH, LH, and testicular function.

LH rises were observed within minutes of IV bolus administration in the George 2011 and George 2013 study designs.^[5][6] KP-10's approximately 4-minute plasma half-life and its direct activation of GnRH neurons explain the rapid onset. Subcutaneous administration has a slower absorption phase; precise onset timing from SC routes is less characterized in the published literature.

Continuous high-dose infusion in research settings produced receptor desensitization and paradoxical LH suppression — tachyphylaxis. Twice-daily SC injections for 14 days caused the LH response to fall from ~24 IU/L on day 1 to ~2.5 IU/L by day 14 (Jayasena 2009, JCEM).^[8] Pulsatile or intermittent protocols were explored to preserve KISS1R sensitivity. No serious adverse events were reported at any dose studied in the clinical literature.^[22]

As the master upstream regulator of the reproductive hormone axis, kisspeptin activates KISS1R on GnRH neurons, initiating the hormonal cascade governing puberty, fertility, and reproductive cycling. Exogenous kisspeptin peptide administration in research settings produced LH and FSH elevation, testosterone normalization, and oocyte maturation triggering across published human trials.^{[5][6][9][10]}

Five clinical research arms: (1) reproductive-axis probe — using LH response as a readout of HPG-axis function; (2) hypothalamic amenorrhea — restoring GnRH pulsatility; (3) IVF oocyte maturation — as a safer alternative to hCG triggering in OHSS-risk patients; (4) hypogonadism and testosterone research — studying upstream LH stimulation; (5) psychosexual disorders — fMRI studies of sexual brain processing in HSDD.^{[5][7][9][13][14]} All applications remain investigational.

No. Kisspeptin remains an investigational peptide; no formulation has received FDA approval for any clinical indication as of 2025 (Velmurugan 2025, Current Medicinal Chemistry).^[22] Multiple Phase 1/2 trials have been completed; no Phase 3 trials or NDA submissions have been identified in public databases.

Both activate KISS1R fully. KP-10 is the shortest fully active C-terminal fragment (10 AA, 1302.5 Da) with a plasma half-life of approximately 4 minutes in humans and clearance within 30 minutes of IV bolus. KP-54 is the primary endogenous 54-amino-acid form (6142 Da) with a plasma half-life of approximately 27–32 minutes, a longer LH-stimulation window (1–4 hours vs 10–60 minutes), and demonstrated superiority for IVF triggering and hypothalamic amenorrhea infusion protocols.^[12]

KP-10: approximately 4 minutes in humans (3.8 ± 0.3 min in men, 4.1 ± 0.4 min in women). KP-54: approximately 27–32 minutes in humans. The roughly 8-fold difference results from KP-54's larger size conferring greater resistance to endopeptidase cleavage. This difference determined which isoform was used in which trial type: KP-10 for mechanistic bolus studies, KP-54 for IVF and HA protocols requiring sustained effect.^[12]

KISS1 was cloned in 1996 at Hershey Medical Center as a melanoma metastasis suppressor — named for its discovery in Hershey, Pennsylvania.^[17] Its reproductive role was discovered in 2003 when two independent groups published findings on KISS1R knockout mice and GPR54-mutation patients with absent puberty.^[1] KISS1 encodes the 145-amino-acid kisspeptin precursor protein from which all active kisspeptin fragments are cleaved.

Kisspeptin binds KISS1R (formerly GPR54 / AXOR12), a Gq/11-coupled G-protein-coupled receptor. Loss-of-function KISS1R mutations cause idiopathic hypogonadotropic hypogonadism and absent puberty onset (Seminara 2003, NEJM).^[1] Gain-of-function mutations cause central precocious puberty (Teles 2008, NEJM).^[2] The conserved C-terminal RF-amide motif of kisspeptin is required for receptor binding.

Kisspeptin binds KISS1R on hypothalamic GnRH neurons, driving GnRH pulses that stimulate LH and FSH release from the pituitary and downstream gonadal hormone production. At the cellular level: KISS1R activation → Gq/11 → PLC → IP3 → intracellular calcium release → GnRH-neuron depolarization (~6 mV, ~21 min duration).^[4] KNDy neurons in the arcuate nucleus act as the pulse generator: NKB initiates, dynorphin terminates, kisspeptin transmits to GnRH neurons.^[15]

By driving an endogenous LH surge, yes — in the IVF context. KP-54 at 9.6 nmol/kg SC was used to trigger oocyte maturation in IVF studies, including in women at high risk of OHSS where hCG-triggered OHSS was a concern. Zero OHSS cases and a 62% live birth rate were documented in the Phase 2 RCT (Abbara 2015, JCEM).^[9] Kisspeptin drives ovulation via an endogenous LH surge rather than by directly stimulating ovarian receptors.

KP-54 was studied as an IVF oocyte maturation trigger and to restore reproductive hormone cycling in hypothalamic amenorrhea. IVF outcomes from peer-reviewed Phase 2 trials are positive: 95% oocyte maturation, 62% live birth rate, zero OHSS at the optimal dose.^[9] HA restoration was documented acutely but limited by tachyphylaxis with chronic dosing.^[7][8] No formulation is approved for clinical fertility treatment.

Continuous infusion studies observed tachyphylaxis; twice-daily SC administration for 14 days reduced the LH response from ~24 IU/L to ~2.5 IU/L (Jayasena 2009, JCEM).^[8] Pulsatile or once-daily protocols were explored to preserve KISS1R sensitivity. The short plasma half-life of KP-10 (~4 min) means the receptor may reset between well-spaced doses.

fMRI studies at Imperial College (Mills 2023, JAMA Network Open) found kisspeptin enhanced activity in brain regions associated with sexual and emotional processing in men with HSDD (Cohen d = 0.81), with a 56% increase in penile tumescence above placebo.^[13] A parallel trial in women with HSDD found hippocampal and posterior cingulate modulation correlating with reduced sexual dysfunction measures (Thurston 2022, JAMA Network Open).^[14]

Kisspeptin drives an endogenous LH surge through the hypothalamic-pituitary pathway rather than directly activating ovarian LH/hCG receptors. This physiological distinction is hypothesized to confer lower OHSS risk in high-responder patients. The Abbara 2015 Phase 2 RCT demonstrated zero OHSS at any tested kisspeptin-54 dose with a 62% live birth rate — the data underpinning this hypothesis.^[9]

Cortisol and stress-axis mediators (CRH, beta-endorphin) suppress hypothalamic kisspeptin neuron activity, reducing GnRH pulsatility. This provides the biological explanation for stress-induced hypothalamic amenorrhea: low energy availability, excessive exercise, and psychological stress all converge on kisspeptin neuron suppression as the final common pathway before GnRH output falls (Patel 2024, Ann NY Acad Sci).^[20]

The published human evidence is negative for a direct food-intake effect. A 2023 randomized crossover study (n=17, women with overweight or obesity) found IV kisspeptin infusion did not affect self-rated hunger or objectively measured food intake despite confirmed biological activity (elevated LH) (Izzi-Engbeaya 2023, Diabetes Obes Metab).^[23] Leptin-kisspeptin interactions in mouse models connect energy status to reproductive function, but direct kisspeptin modulation of food intake in humans was not confirmed.

Metastin is the original name given to the 54-amino-acid KISS1 peptide product when it was first characterized for metastasis-suppressive activity in melanoma. It is now recognized as kisspeptin-54 (KP-54) — the same molecule. The name reflects the peptide's discovery as a KISS1 gene product before its reproductive role was identified.